Cantor Fitzgerald Maintains Overweight Rating for Prenetics, Sets Price Target at $31 After Robust IM8 Growth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Nov 14 2025
0mins
Should l Buy PRE?
Source: Newsfilter
Cantor Fitzgerald's Rating: Cantor Fitzgerald has reiterated its Overweight rating on Prenetics Global Limited (PRE), adjusting the 12-month price target to $31, reflecting updates related to the planned divestment of its Europa business while maintaining a positive outlook on the company's growth strategy.
IM8's Financial Performance: IM8, Prenetics' premium health brand, reported a 568% year-over-year revenue growth in Q3 2025, with revenues of $23.6 million and a gross margin of approximately 60%, alongside a customer payback period of about 3.9 months.
Future Revenue Projections: Cantor forecasts that Prenetics will achieve approximately $217 million in revenue for FY2026, driven by IM8's international expansion and strategic focus, while noting that PRE trades at a lower valuation compared to consumer-health peers.
Bitcoin Treasury and Liquidity: Prenetics holds around 387 BTC valued at approximately $41 million, contributing to a total liquidity of about $120 million, positioning the company favorably in the health and digital asset sectors.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy PRE?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on PRE
About PRE
Prenetics Global Ltd is a company principally engaged in the provision of diagnostic and preventive products and services. The Company operates its business through two segments. The Diagnostics segment is mainly engaged in the sale of precision oncology testing services. The Prevention segment is mainly engaged in the design and sale of genetics testing, including update services, and stool-based deoxyribonucleic acid (DNA) tests for early colorectal cancer screening. The Company's products and services include CircleDNA, ACTOnco, ACTHRD and other products. The in-house developed consumer genetic testing product, CircleDNA, offers comprehensive DNA tests capitalizing on in-house developed testing algorithm. ACTOnco is a comprehensive cancer test used to guide treatment selection for major solid tumors. ACTHRD is a test for the homologous recombination deficiency status of cancer patients. The Company is also engaged in consumer health products by a new health and wellness brand IM8.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Prenetics to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Prenetics Global Limited is set to announce its Q4 and full year 2025 financial results before market open on February 18, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: A conference call will be held the same day at 10:00 a.m. Eastern Time to discuss the financial results in detail, including a Q&A session with analysts, aimed at bolstering investor confidence in the company's future prospects.
- IM8 Brand Achievements: The IM8 brand has surpassed $100 million in annualized revenue within just 11 months of launch and is now sold in over 30 countries, indicating rapid growth and strong market acceptance in the health consumer goods sector.
- Product Innovation: IM8's flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement designed to replace 16 different supplements, showcasing Prenetics' innovative capabilities in science and nutrition, enhancing its competitive edge in the market.
See More
Prenetics Shifts Focus Exclusively to IM8, Projecting FY 2026 Revenue of $180-$200 Million
- Strategic Realignment: Prenetics has announced a complete focus on the IM8 brand, projecting FY 2026 revenue between $180 million and $200 million, indicating strong confidence in the consumer health market and a commitment to future growth.
- Bitcoin Investment Cessation: As of December 4, 2025, Prenetics has halted daily Bitcoin purchases and will not pursue future acquisitions, allowing for a concentration of resources on IM8's expansion, thereby enhancing strategic clarity.
- Financial Robustness: The company maintains a strong financial position with over $70 million in cash and cash equivalents, 510 BTC, and zero debt, providing a solid foundation for the rapid expansion of IM8.
- Market Opportunity Capture: IM8 achieved over $100 million in annualized recurring revenue within 11 months of launch, making it the fastest-growing brand in supplement industry history, showcasing Prenetics' significant market potential and competitive advantage in the health sector.
See More
Presearch Sells Out Inaugural NFT Auction, Exceeding 4 Million Tokens
- Successful Inaugural Auction: Presearch's inaugural Node NFT auction sold out on the first day, with all 142 nodes fetching over 4 million tokens, doubling initial expectations and demonstrating strong market demand for decentralized search networks.
- Community-Driven Model: Each NFT serves not only as a piece of art but also grants holders the right to activate a node, which is expected to enhance network participation and provide rewards to users, further driving the development of Presearch's ecosystem.
- Technical Architecture Upgrade: This auction marks the first phase of the rollout for Presearch 3.0, with a new node orchestration system that will enhance global crawling and indexing capabilities, supporting the retrieval of high-value content and improving user experience.
- Economic Cycle Establishment: By tying node licenses to NFTs, Presearch is testing a new model aimed at enhancing the utility and scarcity of PRE tokens through ongoing auctions, promoting a sustainable economic cycle.
See More
Prenetics Completes 83.4% Warrant Exchange, Reducing Future Dilution Risk
- Warrant Exchange Program: Prenetics has entered into agreements with holders representing approximately 83.4% of its warrants, aiming to simplify its capital structure and significantly reduce future dilution risk, reflecting strong confidence from institutional investors in the revised structure.
- Capital Structure Optimization: The exchange is expected to convert approximately 4.54 million warrants into 2.27 million new Class C warrants, resulting in a 42% reduction in outstanding Class A and B warrants, thereby enhancing the investability of the company's shares.
- Strategic Implications: By eliminating deep out-of-the-money legacy warrants, Prenetics not only lowers dilution risk for shareholders but also improves transparency and investor confidence, enhancing alignment with shareholders.
- Positive Market Response: The participation of the company's largest institutional investors in this plan demonstrates confidence in the company's future growth potential, further solidifying its leadership position in the health sciences sector.
See More
Reasons to Consider Prenetics Global Limited (PRE) as a Strong Momentum Stock: Is It Time to Buy?
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation that they will continue to rise. The Zacks Momentum Style Score helps investors identify stocks with strong momentum indicators.
Prenetics Global Limited Performance: Prenetics Global Limited (PRE) has a Momentum Style Score of B and a Zacks Rank of #2 (Buy), with significant price increases of 23.79% over the past quarter and 150.08% over the last year, outperforming the S&P 500.
Key Metrics for Momentum: The analysis of PRE includes short-term price activity, trading volume, and earnings estimate revisions, which indicate strong investor interest and positive future earnings expectations.
Investment Recommendations: Zacks Investment Research suggests keeping an eye on Prenetics Global Limited as a promising stock pick, alongside other selected stocks that are expected to perform well in the near term.
See More
Presearch Launches First Node NFT Auction Featuring 142 Unique NFTs
- Node NFT Auction Launch: Presearch initiated its first Node NFT auction on December 9, 2025, featuring 142 unique NFTs aimed at incentivizing community operators and enhancing decentralized infrastructure through a community-driven model.
- Innovative NFT Functionality: Each NFT serves not only as a piece of art but also as a license key for operating a node, allowing holders to activate nodes under Presearch 3.0 and earn network rewards, thereby increasing user engagement and network efficiency.
- Technical Architecture Upgrade: This auction marks the first phase of Presearch 3.0, designed to support a decentralized real-time crawling and indexing system that enhances the network's ability to surface high-value, underrepresented content often overlooked by mainstream search engines.
- Simplified Participation Method: Users can participate by creating a Presearch account and depositing PRE tokens to bid, with the highest bidders receiving Node NFTs and corresponding node keys post-auction, fostering interaction and economic incentives between users and the platform.
See More
Prenetics to Release Q4 and Full Year 2025 Financial Results
- Earnings Release Schedule: Prenetics Global Limited is set to announce its Q4 and full year 2025 financial results before market open on February 18, 2026, reflecting the company's commitment to transparency and investor communication.
- Conference Call Details: A conference call will be held the same day at 10:00 a.m. Eastern Time to discuss the financial results in detail, including a Q&A session with analysts, aimed at bolstering investor confidence in the company's future prospects.
- IM8 Brand Achievements: The IM8 brand has surpassed $100 million in annualized revenue within just 11 months of launch and is now sold in over 30 countries, indicating rapid growth and strong market acceptance in the health consumer goods sector.
- Product Innovation: IM8's flagship product, Daily Ultimate Essentials, is an all-in-one powder supplement designed to replace 16 different supplements, showcasing Prenetics' innovative capabilities in science and nutrition, enhancing its competitive edge in the market.
See More
Prenetics Shifts Focus Exclusively to IM8, Projecting FY 2026 Revenue of $180-$200 Million
- Strategic Realignment: Prenetics has announced a complete focus on the IM8 brand, projecting FY 2026 revenue between $180 million and $200 million, indicating strong confidence in the consumer health market and a commitment to future growth.
- Bitcoin Investment Cessation: As of December 4, 2025, Prenetics has halted daily Bitcoin purchases and will not pursue future acquisitions, allowing for a concentration of resources on IM8's expansion, thereby enhancing strategic clarity.
- Financial Robustness: The company maintains a strong financial position with over $70 million in cash and cash equivalents, 510 BTC, and zero debt, providing a solid foundation for the rapid expansion of IM8.
- Market Opportunity Capture: IM8 achieved over $100 million in annualized recurring revenue within 11 months of launch, making it the fastest-growing brand in supplement industry history, showcasing Prenetics' significant market potential and competitive advantage in the health sector.
See More
Presearch Sells Out Inaugural NFT Auction, Exceeding 4 Million Tokens
- Successful Inaugural Auction: Presearch's inaugural Node NFT auction sold out on the first day, with all 142 nodes fetching over 4 million tokens, doubling initial expectations and demonstrating strong market demand for decentralized search networks.
- Community-Driven Model: Each NFT serves not only as a piece of art but also grants holders the right to activate a node, which is expected to enhance network participation and provide rewards to users, further driving the development of Presearch's ecosystem.
- Technical Architecture Upgrade: This auction marks the first phase of the rollout for Presearch 3.0, with a new node orchestration system that will enhance global crawling and indexing capabilities, supporting the retrieval of high-value content and improving user experience.
- Economic Cycle Establishment: By tying node licenses to NFTs, Presearch is testing a new model aimed at enhancing the utility and scarcity of PRE tokens through ongoing auctions, promoting a sustainable economic cycle.
See More
Prenetics Completes 83.4% Warrant Exchange, Reducing Future Dilution Risk
- Warrant Exchange Program: Prenetics has entered into agreements with holders representing approximately 83.4% of its warrants, aiming to simplify its capital structure and significantly reduce future dilution risk, reflecting strong confidence from institutional investors in the revised structure.
- Capital Structure Optimization: The exchange is expected to convert approximately 4.54 million warrants into 2.27 million new Class C warrants, resulting in a 42% reduction in outstanding Class A and B warrants, thereby enhancing the investability of the company's shares.
- Strategic Implications: By eliminating deep out-of-the-money legacy warrants, Prenetics not only lowers dilution risk for shareholders but also improves transparency and investor confidence, enhancing alignment with shareholders.
- Positive Market Response: The participation of the company's largest institutional investors in this plan demonstrates confidence in the company's future growth potential, further solidifying its leadership position in the health sciences sector.
See More
Reasons to Consider Prenetics Global Limited (PRE) as a Strong Momentum Stock: Is It Time to Buy?
Momentum Investing Overview: Momentum investing involves buying stocks that are trending upwards, with the expectation that they will continue to rise. The Zacks Momentum Style Score helps investors identify stocks with strong momentum indicators.
Prenetics Global Limited Performance: Prenetics Global Limited (PRE) has a Momentum Style Score of B and a Zacks Rank of #2 (Buy), with significant price increases of 23.79% over the past quarter and 150.08% over the last year, outperforming the S&P 500.
Key Metrics for Momentum: The analysis of PRE includes short-term price activity, trading volume, and earnings estimate revisions, which indicate strong investor interest and positive future earnings expectations.
Investment Recommendations: Zacks Investment Research suggests keeping an eye on Prenetics Global Limited as a promising stock pick, alongside other selected stocks that are expected to perform well in the near term.
See More
Presearch Launches First Node NFT Auction Featuring 142 Unique NFTs
- Node NFT Auction Launch: Presearch initiated its first Node NFT auction on December 9, 2025, featuring 142 unique NFTs aimed at incentivizing community operators and enhancing decentralized infrastructure through a community-driven model.
- Innovative NFT Functionality: Each NFT serves not only as a piece of art but also as a license key for operating a node, allowing holders to activate nodes under Presearch 3.0 and earn network rewards, thereby increasing user engagement and network efficiency.
- Technical Architecture Upgrade: This auction marks the first phase of Presearch 3.0, designed to support a decentralized real-time crawling and indexing system that enhances the network's ability to surface high-value, underrepresented content often overlooked by mainstream search engines.
- Simplified Participation Method: Users can participate by creating a Presearch account and depositing PRE tokens to bid, with the highest bidders receiving Node NFTs and corresponding node keys post-auction, fostering interaction and economic incentives between users and the platform.
See More
